{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Epkinly"},{"type":"Synonym","name":"epcoritamab"},{"type":"Synonym","name":"DuoBody-CD3xCD20"},{"type":"CodeName","name":"GEN 3013"},{"type":"CodeName","name":"GEN-3013"},{"type":"Synonym","name":"anti-CD20/CD3 bispecific antibody GEN3013"},{"type":"CASRegistryName","name":"2134641-34-0"},{"type":"CodeName","name":"GEN3013"}],"definition":{"html":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab-bysp contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab-bysp binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells.","text":"A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab-bysp contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab-bysp binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/epcoritamab-bysp","text":"Epcoritamab-bysp"},"nciConceptId":"C163022","nciConceptName":"Epcoritamab","termId":798973,"name":"epcoritamab-bysp","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"epcoritamab"}],"links":null}